Legal Notice

LEGAL NOTICES AND DISCLAIMERS

PLEASE READ THIS AGREEMENT CAREFULLY BEFORE ACCESSING THIS WEB SITE. BY ACCESSING THE SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS BELOW. IF YOU DO NOT WISH TO BE BOUND BY THESE TERMS AND CONDITIONS, YOU MAY NOT ACCESS OR USE THIS SITE.

Duska is working hard to ensure that the information provided on this site is accurate and up-to-date but due to the risk that the information may be compromised by software or procedural errors, Duska does not guarantee the accuracy or completeness of the information provided on this site. Duska reserves the right to make changes to the content of this site from time to time without notice or obligation.

Permission to Browse Site and Limited Permission to Make Copies:

You may browse this site for information and may print copies of its contents for your own use. Written permission is required, however, if you want to incorporate the contents into you own site or written materials, create "derivative works" or revise the site contents. In addition, you may not "mirror" the contents of this site without Duska’s permission. To seek permission, please email info@duskatherapeutics.com

Remember:

Although it may be easy to copy in cyberspace, this does not mean it is legal to do so.

Photo Credits:

SnapVillage, ScientificImages.com and Duska Therapeutics.

Copyrights:

Copyright in the pages and in the screens displaying the pages, and in the information and material therein and in their arrangement, are owned by the Duska Therapeutics, Inc. unless otherwise indicated.

Links to Third Party Sites:

Please understand that when you access another web site through this one, Duska can accept no responsibility for your experience with the site. In addition, a link to a non-Duska site does not mean that Duska endorses or recommends that site or its contents.

Stock Information:

The information provided under the Investor Information section of this site is provided through a hypertext link to a third party Web site. (See above for important information about links to third party Web sites.) Under no circumstances will Duska be liable for any loss or direct, indirect, incidental, special or consequential damages caused by reliance on this information or for the risks of the stock market.

Communications with Duska Therapeutics:

Any communications or material transmitted to Duska will be treated as non-confidential and non-proprietary. Duska shall be free to reproduce, use, disclose and distribute these communications to third parties without restriction. Duska Therapeutics shall be free to use any ideas, concepts, know-how or techniques contained in such information for any purpose whatsoever including but not limited to developing, manufacturing, and marketing products incorporating such information.

No Warranties; Limitations of Liability:

Duska assumes no responsibility for errors or omissions on this web site. ACCESS TO THIS SITE IS PROVIDED AS IS WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NONINFRINGEMENT. Duska shall not be liable for any special, indirect, incidental, or consequential damages, including without limitation, lost revenues or lost profits, which may result for the use of this site.

Privacy:

Anyone using this server acknowledges that Duska may monitor the server contents as needed to comply with the law, to protect Duska and visitors to this site or server and to ensure that the server is being operated properly.

Duska Therapeutics, Inc., in La Jolla, California, is a biotechnology company focused on the development of medical products based on adenosine triphosphate and nitric oxide. Duska owns or has exclusive licensing rights to proprietary medical products that are in various stages of development for the treatment and diagnosis of certain cardiac arrhythmias, treatment of heart failure, treatment of chronic obstructive pulmonary disorder, and improvement of sperm motility. For more information, visit http://www.duskatherapeutics.com.

This site may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, The forward-looking statements are based on current expectations, estimates and projections made by management. Duska intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes’’ “seeks,” “estimates,” or variations of such words are intended to identify such forward-looking statements. All statements in this presentation regarding the future outlook related to Duska are forward-looking statements. Additional uncertainties and risks are described in Duska’s most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-QSB and any current reports on Form 8-K filed since the date of the last Form 10-KSB. Copies of these filings are available through the SEC website at www.sec.gov. All forward-looking statements are based upon information available to Duska on the date hereof. Duska undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for certain forward-looking statements. The forward-looking statements contained in this release are subject to certain risks and uncertainties. Actual results could differ materially from current expectations. Among the factors which could affect the Company's actual results and could cause results to differ from those contained in the forward-looking statements contained herein are: the timely commencement and success of the Company's clinical trials and other research endeavors, delays in receiving FDA or other regulatory approvals, the development of competing therapies and/or technologies, the terms of any future strategic alliances, the possible need for additional capital, and any additional factors described from time to time in the Company’s periodic reports on Form 10-KSB and 10-QSB, and any prospectus describing the Company’s securities.

Duska Therapeutics

info@duskatherapeutics.com

At the heart of cardiovascular medicine